Pallas Health vs Luvo Health: Online GLP-1 Plans Compared
Pallas Health vs Luvo Health: Quick verdict — Pallas provides clear, published starting pricing and both brand-name pens and clinician-selected compounded options; Luvo Health’s pricing, renewal terms and coverage details were not verified on the captured landing page and require confirmation before enrollment.
See Pallas Health plans and starting price
Pallas Health vs Luvo Health: what the comparison answers first
This comparison focuses on the most distinctive, supported differences: published starting price and renewal structure, availability of FDA-approved brand-name versus compounded options, how intake and visit requirements are handled online, whether pricing is tied to titration, and regulatory and insurance notes. Every claim below follows the captured source material.
Five quick differences that matter
| Criteria | Pallas Health | Luvo Health |
|---|---|---|
| Starting price | Compounded semaglutide $139 first month; then $597 every 12 weeks (about $199/mo) | Not verified on the captured landing page; confirm current offer |
| Brand-name vs compounded | Offers FDA-approved Wegovy®, Ozempic®, Zepbound® and Mounjaro® or compounded semaglutide/tirzepatide chosen by a clinician | Offers injections and tablets and mentions compounded medications when offered; details not published or verified |
| Online intake and visits | 100% online; asynchronous in most states (43 of 50 need no video visit); video visit required in seven states plus Washington, D.C. | Treatment available only when a licensed clinician determines it is medically appropriate; specific visit model not verified |
| Pricing structure and renewal | Compounded plans priced by medication not by milligram; first-month intro price then renews every 12 weeks | Ongoing support and dose changes are mentioned; current renewal terms and exact pricing were not verified |
| Insurance and regulatory notes | Cash-pay only; eligibility determined by a US-licensed clinician; compounded meds are not FDA-approved | Compounded meds, when offered, are not FDA-approved; other pricing and billing terms should be confirmed |
Pricing transparency and renewal terms
Pallas Health publishes a clear introductory price for compounded semaglutide: $139 for the first month, then $597 every 12 weeks which the copy frames as a $199 per month average. Pallas also states that compounded tirzepatide is $179 first month then $897 every 12 weeks, a $299 per month average. The site notes brand-name cash prices for specific drugs but emphasizes that plan prices include provider care and that compounded plans renew on a 12 week cadence.
Check Luvo Health for current pricing and availability
Availability of brand-name pens versus compounded options
Pallas explicitly offers both FDA-approved brand-name products and clinician-personalized compounded semaglutide or tirzepatide prepared in the USA when a brand medication is not the right fit. Luvo’s captured content references tirzepatide injections, semaglutide injections and tablets and notes compounded medications may be prepared by licensed pharmacies, but the captured landing-page evidence did not publish or verify current product or pricing details. If brand-name versus compounded choice is critical, Pallas documents both paths in the source material while Luvo’s specifics require confirmation.
How online intake, clinician review and state rules compare
Pallas states a US-licensed clinician reviews health history and personalizes the plan and that it is 100 percent online with asynchronous care in most states. Pallas also specifies that a video visit is required in seven states plus Washington, D.C. Luvo’s capture says treatment is available only when a licensed clinician determines it is medically appropriate, but the landing page did not verify the precise intake flow, telehealth format or which states require video.
Start Pallas Health intake and clinician review
Regulatory and billing notes to keep in mind
Both sources include the regulatory caution that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Pallas adds that it is cash-pay only and does not bill insurance, and that treatment may be FSA or HSA eligible with a Letter of Medical Necessity. Luvo’s captured content likewise warns that compounded medications are not FDA-approved and states pricing and terms may change and should be confirmed.
Final comparison and recommendation
On the facts captured: Pallas Health offers clearer, published starting prices for compounded plans, documented brand-name options chosen by clinicians, an explicit 12-week renewal cadence for compounded plans, and a stated online delivery model with asynchronous availability in most states. Luvo Health’s captured landing content shows service offerings and educational resources but did not publish or verify current pricing, renewal terms or state-by-state visit requirements on the captured page, so those details need confirmation before enrolling.
Confirm Luvo Health pricing and eligibility
Choose Pallas Health if you want a published starting price, documented options between FDA-approved pens and compounded preparations chosen by a clinician, and clear renewal terms for compounded plans. Choose Luvo Health if you prefer to verify eligibility, exact costs, pharmacy and state coverage directly with the provider before enrolling because those details were not verified on the captured landing page.